Podcasts about diabetes treatment

Welcome to Ozempic Weightloss Unlocked. Today, we are diving into the latest news and updates on Ozempic, a drug reshaping how we think about weight loss, health, and lifestyle.In the past year, millions of people have turned to Ozempic, part of a group of medications called GLP-1 receptor agonists. Originally created to manage blood sugar for people with type 2 diabetes, Ozempic's appetite-suppressing effects have made it a sought-after tool for weight management. According to the Pennington Biomedical Research Center, these medications were developed from a compound first found in the saliva of the Gila monster lizard. It is amazing to think that a hormone from a desert reptile is now changing lives in clinics around the world.One of the most important updates is accessibility. The White House recently announced a deal with drug makers Eli Lilly and Novo Nordisk to cut prices for Ozempic and related drugs. The average monthly cost, once more than one thousand dollars, could now be as low as fifty to three hundred fifty dollars a month, depending on your insurance. Kim Fisher of the UC Davis Innovation Institute for Food and Health says around one in eight adults in the United States—about forty-one million people—have already used GLP-1 drugs. Lower prices open the door for many more people to take advantage of these treatments.For listeners looking for alternatives to injections, there is more good news. Novo Nordisk recently released results from a study on an oral pill version of Ozempic's sister drug, Wegovy. The New England Journal of Medicine reports that this once-daily pill resulted in an average weight loss of sixteen point six percent—almost identical to the weekly injection. While the pill is not yet approved by the Food and Drug Administration, it may become a game-changer for those seeking a needle-free option. Novo Nordisk says they hope to set a new benchmark for oral weight loss medications pending approval.If you are wondering whether these drugs only affect the scale, the answer is no. According to research from UC Davis and the University of California San Diego, GLP-1 drugs not only promote weight loss, but may also offer broader health benefits. Some of the latest studies show that these medications can lower cardiovascular risk, benefit blood pressure, and even reduce the risk of major events like heart attacks and stroke.Researchers at UC San Diego found that GLP-1 use among people with colon cancer was tied to much lower death rates—fifteen point five percent for those on the drugs, versus thirty-seven point one percent for those who were not. While the exact reasons are still being studied, experts believe these medications reduce inflammation, improve insulin sensitivity, and might even directly inhibit the growth of cancer cells.The way GLP-1 drugs work is by mimicking a natural hormone produced in your gut after eating. They help your body feel full longer, lower blood sugar, and curb cravings—especially for sweets and fatty foods. Patients often report that the constant mental chatter about food is quieter, making it easier to stick to healthy habits.With all the benefits, it is important to mention common side effects. Many users experience nausea, vomiting, or diarrhea, particularly when starting or increasing doses. Doctors recommend pairing treatment with a nutrient-dense diet, regular exercise, and enough protein to help preserve muscle mass.Experts are also discussing the need for ongoing research into the long-term effects and best practices for managing side effects. As these drugs become more widely used, scientists are working to make sure weight loss translates into lasting improvements for health and well-being.That is all for today's episode of Ozempic Weightloss Unlocked. Thank you for tuning in. To stay up to date on the next wave of news and breakthroughs, remember to subscribe. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

A new treatment for Type 1 diabetes that is expected to greatly reduce or eliminate the need for insulin; early cancer detection; fun historical tidbits about grooming, the development of daylight saving time, and past importance of handkerchiefs; and details about the upcoming Jackpot of Opportunities conference and convention of the Kentucky Council of the Blind. Find out more at https://sound-prints.pinecast.co

Welcome to Ozempic Weightloss Unlocked, where we break down the most up-to-date stories in the world of Ozempic, from healthcare breakthroughs to the cultural waves reshaping how we think about weight loss. I am glad you are here.Let us dig into one of the biggest developments making headlines: a national Gallup survey just revealed that the United States is seeing a real decrease in adult obesity rates for the first time in years. This is not just a blip. Experts are linking the trend to the rapid rise in use of GLP-1 medications like Ozempic. According to Healthline and CBS News, the number of Americans using these injectables for weight loss has more than doubled in just the past year, with about twelve percent now reporting current use. Women are leading the charge in use and have seen slightly bigger drops in obesity rates compared to men.The story does not stop with adults. Think Global Health points out that Ozempic and similar drugs are being prescribed more frequently to adolescents, with use in children and teens increasing by nearly six hundred percent over the last five years. This surge follows Food and Drug Administration approval for ages twelve and up, but experts caution that pediatric guidelines and global access remain uneven.Back to the grown-ups: age seems to be a key factor. According to Gallup's analysis, adults between forty and sixty-four years old are using these medications most and have had the greatest reductions in obesity rates. Meanwhile, older Americans show higher rates of using these drugs but do not see as big an impact on their obesity numbers.Now, what is happening in the body when someone takes Ozempic? These medications work by mimicking hormones in the gut that help control appetite. They make you feel full longer, reduce hunger, and even curb cravings for fatty foods. The result is, as Medical News Today explains, many people lose meaningful weight — and maintain improvements in blood sugar, blood pressure, and cholesterol levels.But here is something that might surprise you. According to a large international study led by University College London and shared in Science Daily, Ozempic does not just help with weight. It reduces the risk of heart attack and stroke by about twenty percent, even for people who do not lose a lot of weight while on the drug. Researchers saw these heart benefits for people across a range of body types. The study found that a reduction in waist size did explain some of the improvement in heart health, but a full two-thirds of the benefits seemed unrelated to weight loss alone, which suggests Ozempic may support heart health through other mechanisms.Let us talk long-term results, because listeners want to know what happens after the initial weight loss. New research shared in the Cochrane Database of Systematic Reviews and reported by major health outlets compared Ozempic to other leading medications. Drugs like Mounjaro helped patients lose up to sixteen percent of their body weight over twelve to eighteen months and keep it off for as long as three and a half years. For Ozempic, the sustained weight loss averaged eleven percent over sixteen months, with benefits lasting for around two years. All of these drugs outperformed older medications in long-term trials.However, experts say it is important to be aware of the whole picture. Like all medications, Ozempic and similar drugs come with side effects. The most common are digestive issues like nausea, constipation, or diarrhea, along with headaches and abdominal pain. Fatigue can occur too. And doctors stress that weight management with these drugs is not quick or effortless. It is a long-term process that requires commitment to healthy habits in diet and movement for the results to last.One final thought: as usage spreads, voices like the Pew Research Center note that most Americans now see these medications as a good option for people with true weight-related health issues. Still, a sizeable stigma remains about using them for non-medical reasons.Thank you for tuning in to Ozempic Weightloss Unlocked, where the science and stories making headlines come straight to your headphones. Do not forget to subscribe for all the latest news on Ozempic and its impact on health, lifestyles, and beyond.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Today, we're exploring the latest updates on Ozempic, a medication that's gained widespread attention for its role in weight loss. Originally approved for type 2 diabetes, Ozempic has shown significant potential in reducing body weight as a side effect. Its active ingredient, semaglutide, works by mimicking a natural hormone called glucagon-like peptide-1, which helps regulate blood sugar and appetite.Ozempic can lead to an average weight loss of about 7% of body weight over several months. However, not everyone experiences this benefit, as results can vary based on individual factors like diet and overall health. Semaglutide is also used in Wegovy, which is specifically approved for weight management and offers a higher dose.Beyond weight loss, semaglutide has been found to have cardiovascular benefits, reducing the risk of heart attacks and strokes regardless of the amount of weight lost. This suggests that its effects extend beyond just weight management.Thank you for tuning in. Be sure to subscribe for more updates on Ozempic and other health topics. This has been a Quiet Please production, for more check out Quiet Please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

I am thrilled to have Gary Taubes back on the show today. (He was with me before on episode 137. Gary is an investigative science and health journalist whose work has been pivotal in catalyzing the low-carb keto movement. He has written many books, including his most recent, Rethinking Diabetes, and his articles are in many of the best anthologies. He has also received many science awards. Today's discussion is particularly significant, given the recent report from the American Diabetes Association revealing that the annual cost of diabetes in the United States reached a staggering $412.9 billion in 2022, with individuals diagnosed with diabetes now representing one in every four dollars spent on healthcare.  In our discussion today, we dive into the history of diabetes, pertinent statistics, the prevailing standard of care, and the transformative influence of insulin on diabetes management and reactive hypoglycemia. Gary provides insights into his reactions to GLP ones, the integration of medical and nutrition science into the medical field, and the influence of organizations such as the American Diabetes Association, AHA, USDA, and NIH. Our discussion also extends to the effects of pharmaceuticals, the shortcomings in our approach to diabetes management and existing models, and the challenge the low-carb community faces. Stay tuned for today's eye-opening conversation, where we shed light on the complexities surrounding diabetes care, explaining how simple lifestyle changes can tremendously improve quality of life. IN THIS EPISODE YOU WILL LEARN: Rethinking Diabetes is a groundbreaking exploration of diabetes diagnosis, management, and treatment Gary discusses the evolution of evidence-based medicine Why the traditional medical approach to treating diabetes is inadequate How the guidelines of the American Diabetes Association were based on outdated assumptions  How medical treatments compare with lifestyle changes for managing diabetes Controversies surrounding how the pharmaceutical industry has influenced the way medical associations have shaped their diabetes management policies How medical guidelines and dietary advice have evolved What constitutes a healthy diet? How patients often have trouble following diet recommendations, despite their best intentions Is obesity a hormonal disorder or caused by overeating?  Connect with Cynthia Thurlow Follow on X, ⁠Instagram⁠ & ⁠LinkedIn⁠ Check out Cynthia's ⁠website⁠ Submit your questions to support@cynthiathurlow.com Connect with Gary Taubes On his ⁠website⁠ X ⁠Facebook⁠ Previous Episode Mentioned ⁠Ep. 137 – High Blood Sugar Levels And Its Long-Term Damage with Gary Taubes⁠ Book Mentioned: Rethinking Diabetes: What Science Reveals About Diet, Insulin, and Successful Treatments is available from most bookstores or on ⁠Amazon⁠.

Welcome to Ozempic Weightloss Unlocked, your podcast for the latest news, research, and practical insights on Ozempic, its medical uses, and the impact on lifestyle and health. Ozempic, known generically as semaglutide, was originally developed for type two diabetes but is now widely prescribed for weight management. According to Women's Health Research Cluster, Ozempic works by mimicking a hormone called glucagon-like peptide-1 that helps you feel fuller longer and slows down how quickly the stomach empties. These effects not only help reduce appetite, but also keep blood sugar stable. That is why demand for these medications has skyrocketed over the past few years.Clinical trials consistently show notable results. Multiple large studies, as summarized in the National Library of Medicine, reveal that up to 14 to 16 percent body weight loss can be sustained for more than a year. Even higher percentages are seen when combined with behavioral therapy and a low-calorie diet. Some studies on similar drugs, like tirzepatide, report weight loss as high as 20 percent over seventy-two weeks. These numbers put Ozempic and its peers at the center of conversation around obesity and metabolic health.Real-world factors do impact results. New York University research presented at the American Society for Metabolic and Bariatric Surgery compared Ozempic and similar drugs to bariatric surgery. Surgery produced five times the weight loss of medication, averaging more than 25 percent body weight lost over two years. Researchers noted that regardless of the method, consistency is key. Medications only work as long as they are taken, while surgery is a permanent change.For those considering Ozempic, there are some noticeable bodily effects. Medical News Today discusses “Ozempic legs,” a term for changes in leg appearance during rapid weight loss, such as thinner or frailer legs and sometimes loose skin. This can result from losing both fat and muscle. Up to forty percent of weight lost on semaglutide may come from lean body mass, not just fat. To address this, experts recommend eating enough protein, incorporating regular strength training, and losing weight gradually to preserve muscle and skin elasticity.Another area of emerging research is how these GLP-1 drugs affect alcohol metabolism. The Fralin Biomedical Research Institute found that medications like Ozempic can slow how quickly alcohol enters the bloodstream, delay its effects on the brain, and potentially reduce alcohol use. These findings suggest the drugs may play a future role in addiction treatment.In terms of safety and tolerability, gastrointestinal symptoms are the most common side effects, such as nausea or upset stomach. These are usually mild or moderate and tend to fade with time. For people with psychiatric conditions such as schizophrenia, data published by National Library of Medicine indicate Ozempic led to significant weight loss without worsening mental health or interfering with medications.When stopping these medications, Women's Health Research Cluster points out weight regain is very likely, as the body's metabolic adaptations revert without continued GLP-1 stimulation. Long-term studies are ongoing to better understand risks and benefits over many years.There is also growing attention on rare, “unusual” side effects. The Independent and other outlets note that advanced imaging scans became necessary to rule out suspicious findings linked to rapid weight changes when doctors were assessing patients on these drugs. Researchers emphasize this does not mean the drugs cause cancer or other conditions, but it is an important side effect to keep monitoring as usage increases.While Ozempic has made headlines as a “miracle” weight loss medication, experts urge listeners to use it as part of a broader lifestyle approach, including healthy eating, physical activity, and regular medical check-ins. As with any medication, speak with your health care provider about the risks, benefits, and whether this option fits your specific goals and conditions.Thanks for tuning in to Ozempic Weightloss Unlocked. Remember to subscribe so you never miss an update on the latest research and real-world experiences on Ozempic and metabolic health. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest breakthroughs and controversies surrounding Ozempic, its medical use, and its impact on everyday wellness.The big headline this month is the arrival of a new pill form of semaglutide, the main ingredient in Ozempic. According to The New England Journal of Medicine, people who took this daily pill lost almost 14 percent of their body weight over 64 weeks, compared to just 2 percent for those on a placebo. Fifty percent of the patients shed at least 15 percent of their weight, with nearly a third losing 20 percent or more. Novo Nordisk, the company that makes Ozempic, announced even stronger results for those who stuck to their treatment plan, with close to 17 percent average weight loss. This pill, pending approval, could be a game changer for people who prefer not to take injections.On the injectable front, clinical trials featured in The Lancet indicate that a higher 7.2 milligram weekly dose of semaglutide in adults without diabetes led to almost 19 percent average weight loss, higher than what's seen with lower doses. These numbers highlight ongoing efforts to increase the effectiveness of Ozempic for those struggling with obesity.Yet, it's crucial to balance these promising results with real-world insights. The Mayo Clinic and NYU Langone Health recently compared Ozempic's results to traditional weight loss surgery, like gastric bypass and sleeve gastrectomy. Their research revealed that surgery is five times more effective than GLP-1 drugs such as Ozempic, with surgical patients losing an average of 58 pounds after two years versus just 12 pounds for those on the drug for six months. Experts also noted that only 30 percent of patients stick with GLP-1 drugs for longer than a year, and real-world weight loss may be lower than trial results suggest. Surgery, however, isn't without its risks, including potential infections, blood clots, and hernias, and requires strict diet and lifestyle changes afterward.Turning to genetics, Cleveland Clinic research shows that the effectiveness of Ozempic may depend on your DNA. A specific variant in the Neurobeachin gene seems to make some people much more responsive to these medications, leading to 82 percent higher odds of substantial weight loss. This new insight could help doctors tailor treatments so patients get therapies most suited to their genetic profile.Lifestyle stakes are high, and so are concerns about side effects and safety. Recent studies report that Ozempic may cause severe conditions such as gastroparesis, bowel blockages, pancreatic and kidney injuries, and vision problems. Even hair loss is emerging as a potentially significant side effect, especially for women—according to recent findings, female users experienced about twice the rate of hair loss compared to those not using Ozempic.Because of these risks, there are currently over two thousand active lawsuits against Novo Nordisk and other GLP-1 manufacturers, with ongoing multidistrict litigation. These lawsuits allege that the companies did not give enough warning about the dangers, and some patients claim life-changing or life-threatening complications.Compounded GLP-1 drugs, made in pharmacies rather than by pharmaceutical companies, became popular when Ozempic was in short supply. However, the FDA warns that compounded drugs can be risky because they're not evaluated for safety or effectiveness. While the shortage has officially ended, compounded formulations remain in circulation.If you are considering Ozempic—whether as a pill, injection, or a compounded version—talk with your healthcare provider and review your health history, genetic background, and lifestyle goals. Widespread interest has led to changing availability, promising new forms, and more transparent labeling, especially after recent updates about kidney and pancreatic risks.To sum up, Ozempic continues to make waves as both a treatment for diabetes and a potent tool for weight loss. With fresh news about new pill forms, higher effective doses, genetic influences, and ongoing legal cases, it's important to stay informed and make choices based on both science and your personal health needs.Thanks for tuning in to Ozempic Weightloss Unlocked. Don't forget to subscribe to stay up to date on the latest developments. This has been a Quiet Please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Welcome back, listeners, to Ozempic Weightloss Unlocked. Today, we are uncovering the latest news and updates on Ozempic, from its medical applications to its influence on our daily lives and overall health.There is an exciting development in the world of weight loss medication: a pill form of Ozempic, known by its generic name semaglutide. According to The New England Journal of Medicine, those who took the daily semaglutide pill lost nearly fourteen percent of their body weight over sixty-four weeks, compared to just two percent for those who took a placebo. This makes oral semaglutide a potential game changer for those who prefer pills over injections, especially since the pill shows a safety profile similar to the injectable form. Dr. Sean Wharton, who led the recent clinical trial, explained that this oral option could greatly expand the number of people willing to try GLP-1 treatments for obesity.Following closely behind is orforglipron, a new GLP-1 pill developed by Eli Lilly. Fox News reports that in a recent clinical trial, participants taking the highest dose of orforglipron lost an average of more than twenty-seven pounds after a year and a half. Nearly sixty percent of those participants lost ten percent of their body weight, while just under forty percent lost at least fifteen percent. What is even more hopeful, according to the study published in The New England Journal of Medicine, is that those with pre-diabetes saw a sharp improvement in blood sugar levels, suggesting broad metabolic benefits. While the results are compelling, experts note that injectables like Ozempic still deliver slightly more dramatic results, yet many patients may prefer the convenience and ease of a pill.On a different front, research from The Cleveland Clinic has revealed that genetics may influence just how well Ozempic or similar drugs work for you. According to their study, a gene known as Neurobeachin appears to help determine how much weight a person might lose with GLP-1 medications. People with a responsive version of the gene were eighty-two percent more likely to have significant weight loss, while those with a non-responsive score were actually less likely to lose weight. Dr. Daniel Rotroff from the Cleveland Clinic suggests that in the near future, doctors could combine genetic testing with lifestyle and personal factors to tailor obesity treatment, making these therapies even more effective and personalized.Let us not forget the reason why Ozempic was developed in the first place. Originally designed and approved to help manage type two diabetes, Ozempic as well as its higher-dose sibling Wegovy, are now also used for chronic weight management. Both are part of a class called glucagon-like peptide-1 receptor agonists, or GLP-1s. These medications work by stimulating insulin production and helping the body manage appetite and digestion, leading to weight loss as a beneficial side effect. According to information from the Lawsuit Information Center, Ozempic is still mainly prescribed as a once-weekly injection, but with oral versions nearing approval, that could soon change.New treatments often come with questions about safety. According to the United States Food and Drug Administration, there has been increased concern about unapproved compounded versions of these GLP-1 drugs, which have been linked to hundreds of adverse event reports. This highlights the importance of using only medications that are properly prescribed and approved, as safety must always come first.Finally, there are ongoing investigations into rare but serious side effects, such as a risk of vision loss, and digestive issues like gastroparesis linked to GLP-1 drugs including Ozempic. For most people, side effects tend to be mild and include nausea and digestive discomfort, but it is crucial to talk to your doctor to understand the potential risks and benefits as this new generation of weight loss options emerges.That wraps up our update on Ozempic and the evolving world of GLP-1 weight loss therapies. Thanks for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe for more insights, and as always, stay informed and stay healthy. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

David Strain, Associate professor in cardio metabolic health and the clinical lead in the diabetes and Vascular Research Centre at the University of Exeter Medical School

Welcome to Ozempic Weightloss Unlocked, your source for the latest insights on Ozempic—from medical updates to its real-world impact on health and lifestyle.Ozempic, also known as semaglutide, was originally designed to help manage type 2 diabetes, but it has quickly become a leading medication for weight loss. Clinical studies highlighted by Medical News Today and Drugs.com have shown that people using Ozempic can lose between 10 and 17 percent of their body weight over about 68 weeks, with results varying based on dosage and individual response. Some individuals have reported losing as much as 30 pounds in just six months, while also seeing significant improvements in blood sugar levels, such as A1C reductions from 8.5 to 6.2, according to user reviews.But what sets Ozempic apart from other medications like metformin? While both can have modest effects on body weight, Ozempic generally leads to more substantial results. According to Drugs.com, participants in trials with Ozempic and lifestyle changes lost an average of nearly 15 to 17 percent of their weight, far exceeding the modest results commonly seen with metformin.The mechanism is fascinating—Ozempic works by imitating a hormone called GLP-1, reducing appetite and slowing digestion. Yet with such rapid and notable weight loss comes important questions about long-term health. A new study from the University of Virginia, as reported by Science Daily, warns that while GLP-1 drugs like Ozempic deliver dramatic fat loss, they do not appear to improve crucial measures of cardiorespiratory fitness. Moreover, muscle loss is a real concern. Researchers have documented reductions in lean mass when using Ozempic for substantial weight loss, which could impact strength, posture, and even risk of heart problems. To counter this, doctors increasingly recommend combining Ozempic with exercise and a protein-rich diet to help maintain muscle and overall health.With these dramatic results, it's not surprising that Ozempic and similar GLP-1 drugs are making waves far outside strictly medical circles. Weight loss clinics nationwide are rethinking their programs to include these medications, as South County Medspa and Wellness notes, allowing many patients to expect a 10 to 15 percent reduction in body weight over several months. However, these treatments do not come cheap—monthly costs can reach several hundred dollars, leading to high rates of discontinuation as users stop due to expense or side effects, which can include nausea and digestive issues.And what happens if you stop Ozempic? As Professor Patricia Brubaker explains for McGill University, stopping the medication often results in some weight regain—a typical rebound of about 12 percent of what was lost—but most people still hold on to some of their original weight loss a year later. It's not quite the dreaded "yo-yo" effect, but it does highlight the importance of ongoing therapy or lifestyle modification for lasting results.In the realm of new developments, tirzepatide, branded as Zepbound, stands out as the only FDA-approved medication demonstrating even greater weight loss, with some participants losing up to 22 percent of their body weight. Meanwhile, the rise of so-called GLP-1 supplements online is causing concern among Harvard experts. According to Harvard T.H. Chan School of Public Health, these over-the-counter products are not regulated or proven effective, so listeners should approach them with skepticism.As the science evolves and new studies emerge almost weekly, there is a growing recognition among experts: medications like Ozempic can be powerful tools for weight loss, but to truly unlock healthier living, they should be paired with exercise, nutrition, and long-term, individualized care.Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you never miss the latest updates and expert insights. This has been a Quiet Please production, for more check out quietplease dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Welcome to Ozempic Weightloss Unlocked, the show that brings you the most current news and insights on Ozempic, semaglutide, and the world of medical weight loss. Today we are diving into the latest clinical findings, real-life impacts, and debates about the future of this groundbreaking medication.Ozempic, which contains the active ingredient semaglutide, has been a game changer in managing type 2 diabetes, but what is making headlines is its powerful effect on weight loss. Large clinical trials, highlighted by the STEP studies and summarized by Heally and Dr Oracle, show patients on semaglutide 2 point 4 milligrams weekly have lost an average of almost 15 percent of their body weight after about 16 months. That is a remarkable number compared to older options. However, the rise of even newer drugs, such as tirzepatide, is moving the average even higher, up to 22 percent according to recent trials, yet Ozempic remains a trusted and widely prescribed option due to its solid balance of safety and effectiveness.Despite these successes, important new research and medical commentary from University of Virginia and Medical News Today reveal a nuanced picture. Weight loss from Ozempic is not just burning fat—it can also reduce muscle and even affect bone density. People have reported feeling like their strength has faded while using the drug. This loss of lean mass is now under the microscope, with recent studies confirming that a significant fraction of the weight lost may be muscle, not just fat. Maintaining muscle is essential for long-term health, heart function, and quality of life, especially as we age. Scientists and doctors now emphasize the importance of adding resistance exercise and prioritizing adequate protein intake if you or someone you know is using Ozempic for weight loss.Another topic in the headlines is what happens when people stop Ozempic. According to researchers at McGill University, stopping the drug often results in regaining some weight—roughly half of what was lost after a year off treatment. This makes weight maintenance an ongoing process, often requiring sustained lifestyle changes or ongoing medication.Not all Ozempic is created equal, and the Food and Drug Administration is warning consumers to avoid unapproved or counterfeit versions sold online. FDA officials report that unapproved versions may not only be less effective, they can be dangerous, with some found to contain incorrect ingredients or inappropriate dosing. Always get your prescription from a licensed pharmacy, and never buy these drugs labeled as research chemicals or not for human use.Amid booming interest, another trend is the rise of GLP-1 mimicking supplements that claim to offer similar weight loss. According to Harvard experts, these supplements are neither as effective nor as rigorously tested as true semaglutide medications such as Ozempic and Wegovy. For real results and safety, stick with prescribed medications under medical supervision.Before we go, here is a quick roundup. Ozempic and its class of GLP-1 drugs are transforming weight loss medicine, but they come with caveats: possible muscle loss, the potential for weight regain, and uncertainties about long-term impacts beyond the scale, like heart and lung function. Pairing Ozempic with healthy eating, resistance training, and medical guidance gives the best shot at long-lasting health.Thank you for tuning in to Ozempic Weightloss Unlocked. For ongoing updates and deep dives into emerging weight loss science, be sure to subscribe wherever you get your podcasts. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Welcome, listeners, to Ozempic Weightloss Unlocked – your trusted source for the latest news and updates on Ozempic and its impact on health, lifestyle, and medicine.Ozempic, originally developed by Novo Nordisk to help manage type two diabetes, has skyrocketed in popularity for its ability to suppress appetite, slow digestion, and help people achieve significant weight loss. Since its approval in 2017, Ozempic's active ingredient, semaglutide, has not only helped people lower their blood sugar, but has also turned into a twenty-one billion dollar blockbuster thanks to growing demand, celebrity mentions, and viral trends on social media.According to recent coverage on NDTV and Science Alert, millions have experienced meaningful weight loss while on Ozempic and similar appetite-suppressing medications. Reports mention that some users have lost up to twenty pounds or more within just a few months. However, new research from Peking University highlights an important concern: weight loss achieved with Ozempic is often not permanent. Studies analyzed over two thousand participants and found that when patients stopped taking these medications, they typically regained the lost weight—on average, about five and a half pounds within five months of discontinuation. Notably, those who lost the most during treatment tended to gain back more afterward. The underlying reasons for this pattern are not totally clear yet, but the body may undergo changes during weight loss that make it harder to maintain results once the medication is stopped.Aside from weight regain, another consideration is muscle loss. UVA Health researchers have found that while GLP-1 medications like Ozempic can help patients shed fat, about half the weight lost can actually be muscle. Dr. Zhenqi Liu has pointed out that losing muscle, especially those essential for posture and movement, can lower overall fitness and well-being. Because of this, experts recommend maintaining regular exercise routines and ensuring enough protein intake while on these medications to help preserve muscle mass.For those concerned about side effects, reports from The Independent note that although most users tolerate Ozempic well, nausea and digestive issues are common and have, in some cases, led to emergency room visits. But, there is promising news on the horizon: scientists have developed an experimental drug, known for now as TDP, that delivered weight loss in animal studies without causing nausea or vomiting. Human trials are expected to begin within two years.Shifting to broader health impacts, three newly presented studies at the Society of NeuroInterventional Surgery suggest medications like Ozempic may even have brain-protective benefits. Researchers from the University of Wisconsin–Madison found that patients taking Ozempic had a considerably lower risk of stroke-related death compared to those not taking the drug, and seemed to recover better post-stroke.Ozempic is also reshaping eating habits on a national scale. Food Dive recently reported that more than six million U.S. adults – about two percent of the population – are taking GLP-1 medications. Studies from the University of Arkansas show that, on average, users of Ozempic consume seven hundred fewer calories a day and tend to cut back on processed foods, sugary drinks, refined grains, and red meat. Grocery spending overall fell by six percent in households with someone on one of these medications. At the same time, consumption of fruits, leafy greens, and water has increased.However, it is crucial to consider possible psychological effects. Business Insider highlights concerns about new or worsened eating disorders among some users, particularly in those with previous histories of restrictive eating. Experts strongly advise against taking these medications without a genuine medical need.The rise of Ozempic and similar medications represents a major shift in how we approach weight loss and chronic disease—but it is not without its caveats. If you or someone you know is considering or already using Ozempic, make sure to consult with a healthcare professional for comprehensive guidance, emphasizing not just the numbers on the scale, but also total health and long-term wellness.That wraps up this episode of Ozempic Weightloss Unlocked. Thanks for tuning in. Be sure to subscribe for more science-backed updates and insights. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.ai

Broadcast from KSQD, Santa Cruz on 6-26-2025: Dr. Dawn opens with groundbreaking results from Vertex Pharmaceuticals' stem cell treatment for severe type 1 diabetes. The experimental therapy, Zimislecel, converts stem cells into pancreatic islet cells and infuses them into patients. In a 12-person study, 10 patients no longer need insulin after one year. The cells migrated to the liver and began producing insulin in response to glucose levels. Patients with hypoglycemic unawareness saw complete elimination of dangerous episodes after three months. However, patients must take lifelong immunosuppressive drugs to prevent rejection. The research represents 25 years of work by Harvard's Doug Melton. A caller asks about Keytruda treatment for melanoma. Dr. Dawn explains it's an immunotherapy drug targeting programmed death receptors that cancer cells hijack to evade immune response. The drug can cause serious immune overreactions but is standard for metastatic melanoma. Treatment protocols depend on cancer staging. For young patients with decades to lose, aggressive treatment is often justified despite risks. An email about morning arthritis pain leads to chronotherapy research discussion. Macrophages have energy levels that peak in the morning when inflammasome activation is quicker and more robust, explaining why arthritis pain is worst after overnight rest. Treatment timing could optimize anti-inflammatory medications by taking them at bedtime. Another email about eye irritation prompts diagnostic discussion. Dr. Dawn recommends examining for bacterial blepharitis before assuming food allergies and testing antihistamine drops. For elimination diets, common allergens include wheat, dairy, corn, soy, and peanuts. However, without other symptoms, food allergies are unlikely causes of isolated eye problems. Dr. Dawn explores advancing CAR-T cell therapy using RNA technology. Traditional therapy costs up to $500,000 per patient requiring lab reprogramming. New RNA-containing nanoparticles temporarily create antigen receptors for about one week. Mouse studies eliminated detectable tumors at highest doses. While effects are temporary, this could dramatically reduce costs and complexity. She discusses DNA forensics evolution from O.J. trial era to current technologies. New paleogenomics technology can analyze fragmented DNA from hair, previously considered unusable. Mitochondrial DNA analysis can definitively exonerate suspects. This led to Charles Fane's release after 17 years on death row when hair evidence proved innocence and identified the actual perpetrator. Dr. Dawn introduces Barrett's esophagus screening replacing invasive endoscopy. Patients swallow a capsule containing a compressed sponge that expands in the stomach and is pulled out via string, collecting esophageal cells. The test identifies abnormalities with 100-fold increased cancer risk when positive and 98% accuracy when negative, allowing targeted endoscopy only for high-risk patients. She concludes discussing body composition analysis superiority over BMI. Studies found overweight BMI showed 3.6 times higher heart disease risk, while large waist circumference showed four times higher risk. However, BMI had no significant relationship with overall mortality. Dr. Dawn advocates for bioimpedance analysis devices to measure body fat percentage and track muscle loss.

Broadcast from KSQD, Santa Cruz on 6-26-2025: Dr. Dawn opens with groundbreaking results from Vertex Pharmaceuticals' stem cell treatment for severe type 1 diabetes. The experimental therapy, Zimislecel, converts stem cells into pancreatic islet cells and infuses them into patients. In a 12-person study, 10 patients no longer need insulin after one year. The cells migrated to the liver and began producing insulin in response to glucose levels. Patients with hypoglycemic unawareness saw complete elimination of dangerous episodes after three months. However, patients must take lifelong immunosuppressive drugs to prevent rejection. The research represents 25 years of work by Harvard's Doug Melton. A caller asks about Keytruda treatment for melanoma. Dr. Dawn explains it's an immunotherapy drug targeting programmed death receptors that cancer cells hijack to evade immune response. The drug can cause serious immune overreactions but is standard for metastatic melanoma. Treatment protocols depend on cancer staging. For young patients with decades to lose, aggressive treatment is often justified despite risks. An email about morning arthritis pain leads to chronotherapy research discussion. Macrophages have energy levels that peak in the morning when inflammasome activation is quicker and more robust, explaining why arthritis pain is worst after overnight rest. Treatment timing could optimize anti-inflammatory medications by taking them at bedtime. Another email about eye irritation prompts diagnostic discussion. Dr. Dawn recommends examining for bacterial blepharitis before assuming food allergies and testing antihistamine drops. For elimination diets, common allergens include wheat, dairy, corn, soy, and peanuts. However, without other symptoms, food allergies are unlikely causes of isolated eye problems. Dr. Dawn explores advancing CAR-T cell therapy using RNA technology. Traditional therapy costs up to $500,000 per patient requiring lab reprogramming. New RNA-containing nanoparticles temporarily create antigen receptors for about one week. Mouse studies eliminated detectable tumors at highest doses. While effects are temporary, this could dramatically reduce costs and complexity. She discusses DNA forensics evolution from O.J. trial era to current technologies. New paleogenomics technology can analyze fragmented DNA from hair, previously considered unusable. Mitochondrial DNA analysis can definitively exonerate suspects. This led to Charles Fane's release after 17 years on death row when hair evidence proved innocence and identified the actual perpetrator. Dr. Dawn introduces Barrett's esophagus screening replacing invasive endoscopy. Patients swallow a capsule containing a compressed sponge that expands in the stomach and is pulled out via string, collecting esophageal cells. The test identifies abnormalities with 100-fold increased cancer risk when positive and 98% accuracy when negative, allowing targeted endoscopy only for high-risk patients. She concludes discussing body composition analysis superiority over BMI. Studies found overweight BMI showed 3.6 times higher heart disease risk, while large waist circumference showed four times higher risk. However, BMI had no significant relationship with overall mortality. Dr. Dawn advocates for bioimpedance analysis devices to measure body fat percentage and track muscle loss.

See omnystudio.com/listener for privacy information.

Diabetes treatments sky rocket.  Drug prices up.  Patients up 142K to 1.5 million.  Hairloss and ED meds not covered.  "Upcoding" beware of fraud (United Healthcare says accusations are false)  Agentic AI - Using AI as agents to help the customer.  23 and me files for bankruptcy.

This is a free preview of a paid episode. To hear more, visit abbieattwoodwellness.substack.comRegistered dietitian and diabetes care specialist Janice Dada joins the show this week to explore diabetes management from a non-diet, weight-inclusive lens.Tune in to unpack the myths that dominate diabetes care — from the demonization of rice and bread, to fears about processed foods, to the idea that weight loss is a solution, to the panic that surro…

The Cincinnati Health Network serves individuals experiencing homelessness or living with HIV/AIDS in the Tri-State area. They provide the following services at all their locations: Physical Exams, Blood Tests, Medication Assistance, Drug and Alcohol Abuse Screening & Treatment, Smoking Cessation Help, Diabetes Treatment and Education, Dental Referrals, Pregnancy testing, Testing Read More Shared by United Resource Connection April 10, 2025

Listen Saturday mornings at 8 as Dr. Msonthi Levine discusses medical issues and takes your calls on News Talk 560 KLVI. Dr Levine is board certified in Internal Medicine and Geriatrics. His office is located at 3080 Milam in Beaumont, Texas. He can be reached at 409-347-3621.

Subscriber-only episodeResources for the Community:___________________________________________________________________https://linktr.ee/theplussidezpodcast Ro - Telehealth for GLP1 weight management https://ro.co/weight-loss/?utm_source=plussidez&utm_medium=partnership&utm_campaign=comms_yt&utm_content=45497&utm_term=55______________________________________________________________________The Provider Spotlight is a new bonus series of shorter episodes featuring doctors and specialists from past sessions—think of it as 'doctor shorts.' With over 25k scripts for Zepbound written weekly, many new subscribers haven't seen our earlier episodes, which helps them catch up quickly. Thanks for your support!On August 28th of 2023 Dr Contessa Metcalfe from Marreid to Medicine setdown with the Plus Sidez Podcast and shared her unique perscriptive on treating Obesity, Diabites with GLP-s. ______________________________________________________________________⭐️Mounjaro Stanley⭐️griffintumblerco.Etsy.comUse code PODCAST10 for $ OFF______________________________________________________________________Join this channel to get access to perks:   / @theplussidez______________________________________________________________________#Mounjaro #MounjaroJourney #Ozempic #Semaglutide #tirzepatide  #GLP1 #Obesity #zepbound #wegovy  Kim Carlos, Executive Producer TikTok https://www.tiktok.com/@dmfkim?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/dmfkimonmounjaro?igsh=aDF6dnlmbHBoYmJn&utm_source=qr Kat Carter, Associate Producer TikTok https://www.tiktok.com/@katcarter7?is_from_webapp=1&sender_device=pc Instagram https://www.instagram.com/mrskatcarter?utm_source=ig_web_button_share_sheet&igsh=ZDNlZDc0MzIxNw==

Send us a textWe talk to John Dennis, a data science researcher working in the University of Exeter. He used data from 1 million people with Type 2 diabetes to discover how the clinical characteristics of a patient alter the glucose lowering with different treatments. John's 5 drug model, published in the Lancet in late February 2025, uses simple clinical information to identify, for the first time, the best glucose lowering treatment for a patient.  The model selected best treatment lowers the glucose most, doubles  the time before another medication is needed and reduces long term complications of diabetes. See www.1in6b.com for more details. 

Sean Saint, CEO of Beta Bionics (BBNX), discusses the company's IPO today and what the company does. Beta Bionics' “bionic pancreas” is “the most automated” system to help control diabetes on the market, he says. He discusses why the system is better than regular insulin pumps, including its ability to learn and adapt, and how patients can access it. ======== Schwab Network ======== Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185 Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7 Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore Watch on DistroTV - https://www.distro.tv/live/schwab-network/ Follow us on X – https://twitter.com/schwabnetwork Follow us on Facebook – https://www.facebook.com/schwabnetwork Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

As 2024 comes to a close, join EMJ Editor, Evgenia Koutsouki as she counts down the standout moments from the past year in the final instalment of our Highlights series. This special episode revisits the top six podcasts from 2024, showcasing the groundbreaking ideas, innovations, and expert insights that shaped the healthcare landscape. From exploring the genetic mysteries of parasitic infections to pioneering biosensors for gut health, this festive wrap-up celebrates a year of exceptional conversations and transformative research.   Timestamps:     (00:00)-Introduction   (00:56)-Intersection between parasitology and genetics   (05:55)-Learning from individuals with low cholesterol   (09:56)-Continuous glucose monitoring and insulin pumps   (13:43)-Brain-gut behavioural therapy   (18:47)-Biosensors to treat gut inflammatory disorders   (21:59)-Microbiome monitoring  (25:50)-Wrap up    Featured Episodes:  The Fate of the Cell  Innovations in Vascular Medicine: From Bench to Bedside  A Personalised Approach to Diabetes  Gut Instincts: Bridging Psychology and Gastroenterology  Agar Art and Biosensor Breakthroughs  Microbe Monitoring: New Frontiers in Pathogen Surveillance 

DISCLAMER >>>>>>    The Ditch Lab Coat podcast serves solely for general informational purposes and does not serve as a substitute for professional medical services such as medicine or nursing. It does not establish a doctor/patient relationship, and the use of information from the podcast or linked materials is at the user's own risk. The content does not aim to replace professional medical advice, diagnosis, or treatment, and users should promptly seek guidance from healthcare professionals for any medical conditions.   >>>>>> The expressed opinions belong solely to the hosts and guests, and they do not necessarily reflect the views or opinions of the Hospitals, Clinics, Universities, or any other organization associated with the host or guests.       Disclosures: Ditch The Lab Coat podcast is produced by (Podkind.co) and is independent of Dr. Bonta's teaching and research roles at McMaster University, Temerty Faculty of Medicine and Queens University. Welcome to another episode of "Ditch the Lab Coat," the podcast where we critically explore the latest in medical science and healthcare with engaging discussions and a dose of skepticism. I'm your host, Dr. Mark Bonta, and today we have an insightful conversation lined up with our distinguished guest, Dr. Allan Detsky. Dr. Detsky, a professor at the University of Toronto and former Chief Physician at Sinai Health Systems, brings his extensive knowledge in evidence-based medicine, health policy, and clinical experience into our discussion.In this episode, we'll delve into the complex landscape of pain management and the opioid crisis, explore the future health challenges posed by climate change and societal shifts in civility, and critique the growing influence of unregulated health advice on social media. Dr. Detsky shares his candid views on the pharmaceutical industry's role in drug development, conflicts of interest, and the intricate relationship between lifestyle changes and medical advancements.We'll also discuss the limitations of evidence-based medicine, especially when it comes to treating patients with multiple conditions, and the challenges of applying clinical guidelines to real-world settings. Plus, stay tuned for an announcement about a website overhaul, launching in December, featuring expanded blog content for our curious listeners.Join us as we unravel these pressing issues and more, always questioning, always learning. "Ditch the Lab Coat" continues right now.00:00 - Podcast begins with healthcare insights from Dr. Alan Detsky.05:31 - Highlighting the role of randomized trials in improving evidence-based medicine.08:52 - Questioning the efficacy of zinc supplements for healthy young adults.10:27 - Clinical study results often fail to align with real patient demographics.16:57 - Lack of shared decision-making opportunities for hospitalized patients.19:22 - Discussing right-wing skepticism toward pharmaceutical companies, balanced with acknowledgment of their contributions.21:21 - Exploration of how pharmaceutical companies prioritize profits over public-interest-driven drug development.25:00 - Reflecting on personal and professional relationships with drug industry figures.30:43 - Increasing dependency on lifelong medications in healthcare.35:14 - Potential for AI to address systemic issues despite its resource demands.36:35 - Emphasizing the importance of verifying credentials to avoid unqualified healthcare professionals.

Board-certified in endocrinology, Dr. Gupta will discuss advancements in diabetes treatment.

In this edition of The Naked Scientists: The new form of insulin that switches itself off before blood sugar falls too low; also, scientists suss out the origins of most of the meteors that fall to Earth; and why the longest lived patch of snow in the Scottish Highlands finally looks set to melt away... Like this podcast? Please help us by supporting the Naked Scientists

In this episode, Dr Ron Ehrlich speaks with Dr James Muecke, Australian of the Year 2020, about his mission to reverse type 2 diabetes through diet and lifestyle changes. Dr. Mueke shares insights from his work with Defeat Diabetes and the recent partnership with Diabetes Australia, promoting a low-carb, healthy-fat approach. They discuss how addressing insulin resistance can transform health and why it's time to rethink conventional diabetes management. This conversation is essential for anyone seeking a sustainable, holistic approach to diabetes prevention and long-term wellness. ----  Shownotes are available at Dr James Muecke: The Future of Diabetes Treatment ----  Join the Unstress Health Community & Transform Your Life! https://bit.ly/3SRq0gg  Connect with Dr Ron at Unstress Health  Instagram: https://www.instagram.com/unstresshealth/  Facebook: https://fb.me/unstresshealth  Email: admin@unstresshealth.com     DISCLAIMER: This podcast provides general information and discussion about medicine, health and related subjects. This content is not intended and should not be construed as medical advice or as a substitute for care by a qualified medical practitioner. If you or any other person has a medical concern, he or she should consult with an appropriately qualified medical practitioner. Guests who speak in this podcast express their own opinions, experiences and conclusions.   See omnystudio.com/listener for privacy information.

Understanding GLP-1 Agonists: A Comprehensive Guide Part I: The Evolution From Diabetes Treatment to Weight Loss   "Going on a medication for weight loss is NOT the easy way out."  - Dr. Ali    Detailed Synopsis   In this first of three episodes about GLP-1 agonists, Dr. Ali Novitsky, your favorite Obesity Medicine and Fitness expert, dives deep into the science and history of GLP-1 agonist medications to educate her listeners on the realities and benefits of these medications. Dr. Novitsky starts with a personal story from Ocean City, New Jersey, where she encountered a woman whose family members were using GLP-1 agonists. The woman, however, had little understanding of how these medications work—prompting Dr. Ali to address common misconceptions. Dr. Novitsky emphasizes that GLP-1 agonists are not a quick fix but a helpful tool for those dealing with metabolic health challenges. She traces the history of GLP-1 agonists, starting from the 1970s, and highlights their role in treating diabetes since the 1990s. The episode explains the secondary effect of weight loss these medications can produce, underlining that their use must be accompanied by lifestyle changes for optimal success.   Mechanism of GLP-1 Agonists   Dr. Novitsky provides a clear breakdown of how GLP-1 agonists work in the body, specifically differentiating between types such as semaglutides and terzepatides, each with varying effects on weight loss. She debunks the myth that these medications offer an "easy way out" and emphasizes the importance of combining them with exercise and diet for best results. This segment covers why lifestyle changes are essential for those using GLP-1 agonists.   Criteria for Candidacy and Addressing Concerns   The episode also explores the criteria for being a candidate for GLP-1 agonists, stressing that BMI numbers alone are not enough. Dr. Novitsky explains how conditions like insulin resistance and leptin resistance factor into the equation. She advocates for personalized medicine and ensures that GLP-1 agonists are prescribed with a focus on improving overall metabolic health and preventing chronic diseases. Dr. Novitsky thoughtfully addresses concerns about side effects and the involvement of pharmaceutical companies in promoting these medications. She emphasizes the importance of compassion and a holistic approach to caring for individuals on these medications.   Looking to the Future: Preventive Health and Longevity   Dr. Novitsky envisions the future of GLP-1 agonists in preventive healthcare. She shares her predictions for microdose medications as an early intervention to support long-term health and longevity. Before wrapping up, Dr. Ali discusses her fitness and coaching programs, providing listeners with practical tools to achieve their health goals. Dr. Ali Novitsky's podcast continues to be a rich source of education, offering insights into both the mental and physical aspects of health, and breaking down the facts vs. myths surrounding GLP-1 agonists.  The goal is to empower listeners to be better equipped to make informed decisions on their health journey.   Time Stamps  [00:02] Introduction and personal story about GLP-1   [07:45] Common misconceptions about GLP-1 agonists   [15:30] History of GLP-1 agonists and their use in diabetes   [22:10] How GLP-1 agonists support weight loss   [28:35] Criteria for GLP-1 candidacy beyond BMI   [33:50] Addressing side effects and pharmaceutical involvement   [39:12] Importance of lifestyle changes with medication   [46:20] Looking ahead: Microdose medications for longevity   [52:15] Overview of Dr. Novitsky's coaching programs   [56:40] Closing thoughts on compassion and holistic care Resources: The Muscles & Mindset Beginner Strength Training Program - 12 months for only $199! Enroll TODAY. Nutrition Training Program for Healthcare Professionals is enrolling now! You can learn more HERE. Dr. Ali's Advanced Strength Training program is now available for exercises at a higher level. See the details HERE. Optimal GLP-1 Weight Loss Program - next program starts November, 2024.  Learn more and join the waitlist HERE. Transform® 9.0 enrollment is now open! Get started with your bonus content today. Learn more HERE. Follow Dr. Ali Novitsky on TikTok | Facebook | Instagram | YouTube Subscribe to The Muscles and Mindset Podcast on Spotify | Apple Podcasts *Ali Novitsky MD, this podcast, and podcast write-up are NOT providing medical advice. We do not recommend you start any exercise program without first consulting with your doctor!*

Approximately 75 million people with diabetes need to inject themselves daily with insulin. Research led by Dr Nick Hunt of the University of Sydney has developed a new type of oral insulin tablet based on nanotechnology.

My son was diagnosed with type 1 diabetes at the age of 13.Which is why this episode is very close to my heart. There are big life-altering challenges for the patient and their family in managing type 1 diabetes. With limitations to the current insulin therapies that make the work of my guest in the episode, Mike Teiler, all the more important.Mike is the Chief Pharmaceutical Officer at LeviCure, a startup focused on new approaches to type 1 diabetes. In this episode we discuss the difference between type 1 and type 2 diabetes. And explore the development of LeviCure's triple therapy, which combines three existing drugs to improve glycaemic control and potentially achieve remission in type 1 diabetes patients.A therapy that has shown promising results in both recent onset and established patients. We discuss the potential of repurposing existing drugs for the treatment of type 1 diabetes. As well as the funding required and the clinical trial process that will be undertaken to be able to launch the therapy.“Many of them completely stopped insulin injections.” – Mike TeilerYou'll hear about:01:10 - The difference between type & type 2 diabetes04:03 - The lifechanging nature of type 1 diabetes06:40 - The LeviCure story11:16 - The effect of weening people off of insulin 15:08 - Oral drugs that could replace insulin18:48 - Disentangling the honeymoon effect20:15 - The effects on established patients                 25:02 - The pharmaceutical benefits of this therapy27:58 - The intellectual property perspective30:43 - The democratic nature of these new therapies34:15 - What are the clinical phases?41:08 - Making sure the therapies hit the target43:44 - The fundraising needed Follow Mike: LinkedIn - https://www.linkedin.com/in/miketeiler/ LeviCure on LinkedIn - https://www.linkedin.com/company/levicure-ltd/ LeviCure - https://www.levicure.com/  Connect with me:LinkedIn: https://www.linkedin.com/in/markdavison100/ Grant Instruments: https://www.grantinstruments.com/ Grant Instruments on LinkedIn: https://www.linkedin.com/company/grant-instruments-cambridge-ltd/ 

I am thrilled to have Gary Taubes back on the show today. (He was with me before on episode 137. Gary is an investigative science and health journalist whose work has been pivotal in catalyzing the low-carb keto movement. He has written many books, including his most recent, Rethinking Diabetes, and his articles are in many of the best anthologies. He has also received many science awards. Today's discussion is particularly significant, given the recent report from the American Diabetes Association revealing that the annual cost of diabetes in the United States reached a staggering $412.9 billion in 2022, with individuals diagnosed with diabetes now representing one in every four dollars spent on healthcare.  In our discussion today, we dive into the history of diabetes, pertinent statistics, the prevailing standard of care, and the transformative influence of insulin on diabetes management and reactive hypoglycemia. Gary provides insights into his reactions to GLP ones, the integration of medical and nutrition science into the medical field, and the influence of organizations such as the American Diabetes Association, AHA, USDA, and NIH. Our discussion also extends to the effects of pharmaceuticals, the shortcomings in our approach to diabetes management and existing models, and the challenge the low-carb community faces. Stay tuned for today's eye-opening conversation, where we shed light on the complexities surrounding diabetes care, explaining how simple lifestyle changes can tremendously improve quality of life. IN THIS EPISODE YOU WILL LEARN: Rethinking Diabetes is a groundbreaking exploration of diabetes diagnosis, management, and treatment Gary discusses the evolution of evidence-based medicine Why the traditional medical approach to treating diabetes is inadequate How the guidelines of the American Diabetes Association were based on outdated assumptions  How medical treatments compare with lifestyle changes for managing diabetes Controversies surrounding how the pharmaceutical industry has influenced the way medical associations have shaped their diabetes management policies How medical guidelines and dietary advice have evolved What constitutes a healthy diet? How patients often have trouble following diet recommendations, despite their best intentions Is obesity a hormonal disorder or caused by overeating?   Connect with Cynthia Thurlow Follow on Twitter Instagram LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Gary Taubes On his website Twitter Facebook Previous Episode Mentioned: Ep. 137 – High Blood Sugar Levels And Its Long-Term Damage with Gary Taubes Book Mentioned: Rethinking Diabetes What Science Reveals About Diet, Insulin, and Successful Treatments is available from most bookstores or on Amazon.

View Show Notes From This Episode Get Free Weekly Health Tips from Dr. Hyman Sign Up for Dr. Hyman's Weekly Longevity Journal Approximately 1.2 million Americans are diagnosed with diabetes each year​. Understanding the complex nature of this disease is crucial to tackling this widespread health issue. Award-winning science and health journalist Gary Taubes joins me to delve into the history of diabetes and modern treatment options. Together, we explore the use of ketogenic diets, the impact of drugs like Ozempic, and the need to reassess our approach to diabetes management.  In this episode, we discuss: The evolution of diabetes treatment Assumptions about diabetes and the influence of dietary choices The role of calorie intake and exercise in diabetes management The limitations of current drugs used to treat diabetes Clinical trials and their impact on our understanding of diet and health The choice between drug therapy and dietary changes in managing diabetes Join us to discover how bias and ingrained beliefs can obstruct progress in understanding how to treat this chronic illness. This episode is brought to you by Rupa Health, Pique, and BIOptimizers.  Streamline your lab orders with Rupa Health. Access more than 3,000 specialty lab tests and register for a FREE live demo at RupaHealth.com.  Enjoy Pique's Sun Goddess Matcha. Just head over to piquelife.com/hyman with code HYMAN for 15% off + Right now, get up to 15% off + a complimentary beaker and rechargeable frother.  Tackle an overlooked root cause of stress with Magnesium Breakthrough. Visit BIOptimizers.com/Hyman and use code HYMAN10 to save 10%.

The Cincinnati Health Network serves individuals experiencing homelessness or living with HIV/AIDS in the Tri-State area. They provide the following services at all their locations: Physical Exams, Blood Tests, Medication Assistance, Drug and Alcohol Abuse Screening & Treatment, Smoking Cessation Help, Diabetes Treatment and Education, Dental Referrals, Pregnancy testing, Testing Read More Shared by United Resource Connection April 3, 2024

Featured panelist Craig D. Williams, PharmD, FNLA, BCPS, Clinical Professor of Pharmacy Practice at the Oregon Health and Science University joins us to talk about diabetes treatment updates.Listen in as we discuss management of type 2 diabetes, including overcoming hurdles with metformin, GLP-1 agonists, and SGLT2 inhibitors.You'll also hear practical advice from a panelist on TRC's Editorial Advisory Board:Andrea Darby Stewart, MD, Associate Director, Honor Health Family Medicine Residency Program and Clinical Professor of Family, Community & Occupational Medicine at the University of Arizona College of Medicine - PhoenixNone of the speakers have anything to disclose. TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist's Letter or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.The clinical resources mentioned during the podcast are part of a subscription to Pharmacist's Letter and Prescriber Insights: Chart: Drugs for Type 2 DiabetesAlgorithm: Improving Tolerability to MetforminFAQ: Hyperglycemia in the HospitalIf you're not yet a Pharmacist's Letter or Prescriber Insights subscriber, find out more about our product offerings at trchealthcare.com. Follow or subscribe, rate, and review this show in your favorite podcast app. Find the show on YouTube by searching for ‘TRC Healthcare' or clicking here. You can also reach out to provide feedback or make suggestions by emailing us at ContactUs@trchealthcare.com.

On episode 628 of the 40+ Fitness Podcast, we bring back Gary Taubes to discuss his new book, Rethinking Diabetes: What Science Reveals About Diet, Insulin, and Successful Treatments. You can find the full show notes at 40plusfitnesspodcast.com/628.

“Be informed and make your own decision.” —Ann LeMasterArtificial food additives are commonly found in many processed foods and drinks. Unfortunately, studies have shown that these chemicals negatively impact our health in serious ways that we never could imagine. But, there is hope. Making simple lifestyle changes can significantly improve our health and wellness.Hence, this week's episode is focused on providing valuable information for anyone wanting to make more informed choices about their food and better understand common health.Listen in as Ann discusses how artificial food dyes can cause cancer and hyperactivity in children, how artificial sugars can damage our DNA and contribute to leaky gut syndrome, why diabetes is said to be a reversible disease, and more. Connect with Ann on Social Media:  Website: https://seednutrition.com/Annt/home Facebook: https://www.facebook.com/profile.php?id=100008572834952 Instagram: https://www.instagram.com/annthemasterhealer/ Episode Highlights: 03:31 Food Dyes and Their Potential Health Risks08:26  How Sucralose Damages DNA 12:13 Warning Against the Profit-Driven Healthcare System16:25 Diabetes Treatment and Prevention 

I am thrilled to have Gary Taubes back on the show today. (He was with me before on episode 137. Gary is an investigative science and health journalist whose work has been pivotal in catalyzing the low-carb keto movement. He has written many books, including his most recent, Rethinking Diabetes, and his articles are in many of the best anthologies. He has also received many science awards. Today's discussion is particularly significant, given the recent report from the American Diabetes Association revealing that the annual cost of diabetes in the United States reached a staggering $412.9 billion in 2022, with individuals diagnosed with diabetes now representing one in every four dollars spent on healthcare.  In our discussion today, we dive into the history of diabetes, pertinent statistics, the prevailing standard of care, and the transformative influence of insulin on diabetes management and reactive hypoglycemia. Gary provides insights into his reactions to GLP ones, the integration of medical and nutrition science into the medical field, and the influence of organizations such as the American Diabetes Association, AHA, USDA, and NIH. Our discussion also extends to the effects of pharmaceuticals, the shortcomings in our approach to diabetes management and existing models, and the challenge the low-carb community faces. Stay tuned for today's eye-opening conversation, where we shed light on the complexities surrounding diabetes care, explaining how simple lifestyle changes can tremendously improve quality of life. IN THIS EPISODE YOU WILL LEARN: Rethinking Diabetes is a groundbreaking exploration of diabetes diagnosis, management, and treatment Gary discusses the evolution of evidence-based medicine Why the traditional medical approach to treating diabetes is inadequate How the guidelines of the American Diabetes Association were based on outdated assumptions  How medical treatments compare with lifestyle changes for managing diabetes Controversies surrounding how the pharmaceutical industry has influenced the way medical associations have shaped their diabetes management policies How medical guidelines and dietary advice have evolved What constitutes a healthy diet? How patients often have trouble following diet recommendations, despite their best intentions Is obesity a hormonal disorder or caused by overeating?   Connect with Cynthia Thurlow Follow on Twitter, Instagram & LinkedIn Check out Cynthia's website Submit your questions to support@cynthiathurlow.com Connect with Gary Taubes On his website Twitter Facebook Ep. 137 – High Blood Sugar Levels And Its Long-Term Damage with Gary Taubes Book Mentioned: Rethinking Diabetes What Science Reveals About Diet, Insulin, and Successful Treatments is available from most bookstores or on Amazon.

4:00) - Most Interesting | 126. Amputees Feel Warmth In Their Missing Hand(8:40) - Listener Favorite | 118. Robotics & AI in Sheet Metal Forming(12:23) - Most Impactful | 112. Bringing Humans Back Into The Loop For AI(16:30) - Hidden Gem(s) | 135. Reinventing Retail in The Connectivity Age & 144. An implantable device could enable injection-free control of diabetes

November is National Diabetes Month and guest Dr. Angela Thompson is joining NP Pulse to discuss all things related to diabetes and diabetes care. For the last 22 years, Thompson has worked as a Family Nurse Practitioner in the care of both adolescents and adults with diabetes. In this episode, she outlines positive developments in diabetes treatment, discusses the difference between working with adult and adolescent populations and offers advice on how to distinguish diabetes facts from fiction. To learn more about emerging diabetes treatments, enroll in “Clinical Advantage Bootcamp: Type 2 Diabetes Management Certificate for Nurse Practitioners” in the AANP CE Center. This activity offers 8.5 contact hours of continuing education credit, 4.25 of which may be applied toward pharmacology. As a reminder, the 2024 AANP Health Policy Conference is coming soon! Held in Washington, D.C., on Jan. 28-30, this conference will feature sessions for first time attendees like "What You Need to Know About Capitol Hill," and general activities like regulatory updates, a conference keynote and congressional visits. AANP members receive significant discounts on — or free access to — AANP CE activities! You also receive exclusive savings on conference registrations. To view the latest webinars, conferences, regional meetings and more, visit aanp.org/events.        

As the prevalence of diabetes increases, so does the variety of treatment and management tools available to endocrinologists. Alexandra Dodd, M.D., an endocrinologist, discusses advancements including continuous glucose monitoring, new types of long-acting insulin, and medicines that help patients control both blood sugar and weight. She describes the common health conditions that result from advanced diabetes and the corresponding specialists she works with to treat those.

(0:50) - An implantable device could enable injection-free control of diabetes

AP correspondent Jennifer King reports on MED Weight Loss Drug.

Is it possible to reverse type 1 diabetes if caught early enough?

We are lucky to be joined by the "Carb Addiction Doc,” Dr. Robert Cywes. Dr. Cywes works in the trenches and has a wealth of knowledge to share about preventing and managing diabetes. This episode touches on the challenges of balancing conventional and natural approaches to diabetes treatment. Plus, Dr. Cywes discusses the various ways to minimize your chances of developing diabetes and the importance of changing one's mindset to improve health outcomes. This episode is packed with valuable information for anyone looking to prevent diabetes, manage diabetes, and tackle diabetes risk factors.Diabetes: A Growing Problem, a Growing Need for SolutionsMedication is a tool that can be used to treat a variety of medical conditions, including diabetes. However, it is essential to understand that medication alone cannot fix the root cause of the problem. In the case of diabetes, high blood sugar is just the tip of the iceberg. There is much more to be addressed to truly help those with diabetes.Dr. Cywes emphasizes the importance of addressing behavior and treating the cause of the disease. Medication can be used as an accelerant to treatment, but it should not be relied on as the sole solution. Instead, medication should be used in conjunction with lifestyle changes and addressing the root cause of the problem. This can ultimately lead to remission of the disease and the ability to deprescribe medication.CGMs: A Game-Changer for Diabetes CareOne crucial tool for managing diabetes is the continuous glucose monitor (CGM). CGMs provide real-time information about blood sugar levels, which is essential for effective diabetes management. Blood sugar levels should not be a flat line. Instead, blood sugar levels should fluctuate within an appropriate range for each individual. CGMs can help patients understand their blood sugar fluctuations and adjust their diet and medication as needed.Sugar Trap: How to Avoid Insulin Resistance and DiabetesDr. Cywes highlights the adverse effects of excess sugar consumption on insulin resistance. The body has a delicate balance between glucagon and insulin, which work together to stabilize blood sugar levels. However, when excess carbohydrates or protein are consumed, the body prioritizes the storage of these nutrients, leading to insulin dominance instead of glucagon dominance. This can lead to insulin resistance, where the body blocks the insulin receptors to protect cells from the damaging effects of excess sugar.Key Takeaways:[02:31] Treating diabetes beyond blood sugar[07:06] Blood sugar and glucagon[11:53] Insulin and glucagon dominance[17:36] Insulin resistance causes and theories[21:26] Carbohydrates and fat consumption[25:09] Medication for insulin resistance[32:25] Insulin management in diabetes[36:19] Insulin testing and dysregulation[40:11] Glucagon's importance in health[43:04] Satiety hormones and pathways[57:10] Insulin suppression in carnivores[01:03:06] Personalized medicineResources:JSAPA: https://obesityunderstood.comYouTube: https://www.youtube.com/channel/UCk4Mk7vArjSYBa1VKv9-chAInstagram: https://www.instagram.com/carbaddictiondoc/Facebook: https://www.facebook.com/carbaddictiondoc/TikTok: https://www.tiktok.com/@carbaddictioSupport the show

Today, we're exploring a groundbreaking innovation from ETH Zurich that could revolutionize how we power wearable devices. It's time to say goodbye to conventional batteries and hello to a sustainable, continuous, and convenient power source.--Show Notes:(3:00) - Generating power with blood sugarThis episode was brought to you by Mouser, our favorite place to get electronics parts for any project, whether it be a hobby at home or a prototype for work. Click HERE to learn about the future of medical care with next-gen devices & technology.--As always, you can find these and other interesting & impactful engineering articles on Wevolver.com.To learn more about this show, please visit our shows page. By following the page, you will get automatic updates by email when a new show is published. Be sure to give us a follow and review on Apple podcasts, Spotify, and most of your favorite podcast platforms!--The Next Byte Podcast: We're two engineers on a mission to simplify complex science & technology, making it easy to understand. In each episode of our show, we dive into world-changing tech (such as AI, robotics, 3D printing, IoT, & much more), all while keeping it entertaining & engaging along the way.

What are the extraordinary, lasting benefits we may get from a few days of an oatmeal diet?